MAPLEWOOD, NJ, UNITED STATES, August 21, 2025 / EINPresswire.com / -- Olivia Traub, a rising senior at Columbia High School, is leading a regional awareness campaign through community events and social media to educate Jewish communities about their increased cancer risks and the importance of genetic testing. Partnering with Sharsheret , a national nonprofit supporting Jewish women and families facing breast and ovarian cancer, Traub's initiative sheds light on genetic predispositions and BRCA

SOLANA BEACH, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced that U.S. Patent No. 12,377,064 covering the use of GIMOTI® (metoclopramide) nasal spray in patients with moderate to severe symptoms of gastroparesis, has been listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug

STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all owners of class C shares in Sobi. The Board of Directors of Sobi has, as previously communicated, on 15 July 2025 resolved to, conditional upon subscriptio

Plus, news about Benchling, Invivyd, Immuneering, Scilex and Sana Biotechnology: 📉 Sarepta’s debt refinancing: The biotech, which went through a complicated exchange with the FDA this summer over the safety of its Duchenne gene therapy, will extend its debt from 2027 to 2030 to improve its finances. “By extending the maturity of a meaningful portion of our convertible notes to 2030, we have completed a shareholder-friendly transaction,” CEO Doug Ingram said in a statement. Last week, the compan

Neurosurgeons combine embolization and resection in a single procedure for safer outcomes in hypervascular CNS tumors BEIJING , CHINA, August 21, 2025 / EINPresswire.com / -- Hypervascular tumors of the central nervous system (CNS), including meningiomas, hemangioblastomas, and paragangliomas, remain among the most challenging lesions encountered in neurosurgery. These tumors are characterized by a dense vascular network that complicates surgical removal, often obscuring anatomical boundaries an

Multiple Ongoing Phase 2b Studies Advancing HBV Functional Cure Strategy Greater China Partnership with Joincare to Accelerate Development of Critical Care Antibiotic soralimixin Strong Cash Position to Pursue New Discovery Opportunities and Partnership Strategy Conference Calls Scheduled: English Session: August 21 at 9:00 p.m. HKT / 9:00 a.m. ET Chinese Session: August 22 at 9:00 a.m. HKT / August 21 at 9:00 p.m. ET DURHAM, N.C., and BEIJING, Aug. 21, 2025 /PRNewswire/ -- Brii Biosciences Li

NEW CASTLE, Del., Aug. 21, 2025 /PRNewswire/ -- IgniteData, a leader in intelligent clinical trial data automation, is proud to announce the appointment of Dr. David Rhew, Global Chief Medical Officer and Vice President of Healthcare at Microsoft, to its Board of Directors. Dr. Rhew brings decades of experience at the intersection of healthcare, technology, innovation, and clinical research. He pioneered the development of evidence-based order sets integrated into electronic health records (EHRs

CRANBURY, NJ, USA I August 20, 2025 I Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. The hold was lifted in under three months, underscoring the efficiency of the FDA’s revie

Saniona to receive US $42.5 million upfront; potential for development, regulatory and sales milestone payments in addition to royalties on future net sales Jazz obtains exclusive worldwide rights to develop and commercialize preclinical asset SAN2355 in epilepsy and other potential indications For U.S. media and investors only DUBLIN, Ireland and COPENHAGEN, Denmark I August 20, 2025 I Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) and Saniona (Nasdaq OMX: SANION) today announce that the companies ha

– U.S. Food and Drug Administration accepts sNDA for filing with priority review; sets PDUFA goal date of December 20, 2025 — – European Medicines Agency accepts and validates submission for Type II variation MAA for setmelanotide to treat acquired hypothalamic obesity – – Company to host “Commercial Readiness for Acquired Hypothalamic Obesity,” event for investors and analysts on Wednesday, September 24, in Boston – BOSTON, MA, USA I August 20, 2025 I Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM)